Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
Answer from: Medical Oncologist at Academic Institution
I typically avoid immunotherapy and continue the targeted therapy, such as osimertinib, with the chemotherapy.
Sign in or Register to read more